North Jersey Section
American Chemical Society

Discovery, Selection, and Development of Drug Candidates: A Senior Leadership Perspective

Friday, November 17, 2006

Somerset Marriott
110 Davidson Avenue
Somerset, New Jersey 08873

Drs. Paul Feldman, Malcolm MacCoss, Bruce Roth, Carl Decicco, and 2006 OTG Committee

Invited Speakers

  • Dr. P. Roy Vagelos (Retired Chairman and CEO, Merck & Co., Inc.)
    “The Changing Pharmaceutical Industry”
  • Dr. Carl Decicco (Bristol-Myers Squibb)
    “Innovation in Drug Discovery”
  • Dr. Paul Feldman (GlaxoSmithKline)
    “PPAR Pan Agonists-The Next Generation PPAR Ligands”
  • Dr. Malcolm MacCoss (Merck)
    “EMEND(c) (Aprepitant) a potent, orally active Substance P Antagonist for the treatment of Chemotherapy Induced Nausea and Vomiting (CINV), from the medicinal chemistry bench to the clinic”
  • Dr. Bruce Roth (Pfizer)
    “The Discovery and Development of Lipitor”